sign in sign up
<<
Home , Sabcomeline, Silperisone, Sunepitron, Tazomeline, Vedaclidine

PROCLAMATION 7207-^ULY 1, 1999 113 STAT. 2105

Proclamation 7207 of July 1,1999 To Extend Nondiscriminatory Treatment (Normal Trade Relations Treatment) to Products of Mongolia and To Implement an Agreement To Eliminate Tariffs on Certain Pharmaceuticals and Chemical Intermediates

By the President of the United States of America A Proclamation 1. The United States has had in effect a bilateral Agreement on Trade Relations with Mongolia since 1991 and has provided normal trade re­ lations treatment to the products of Mongolia since that time. I have found Mongolia to be in full compliance with the freedom of emigra­ tion requirements of title IV of the Trade Act of 1974 (the "Trade Act") (19 U.S.C. 2432). 2. Pursuant to section 2424(b)(1) of Public Law 106-36, and having due regard for the findings of the Congress in section 2424(a) of said Law, I hereby determine that title IV of the Trade Act (19 U.S.C. 2431-2441) should no longer apply to Mongolia. 3. On November 13, 1998, members of the World Trade Organization (WTO), including the United States and 21 other major trading coun­ tries, announced in the WTO an agreement to eliminate tariffs on cer­ tain pharmaceuticals and chemical intermediates that were the subject of reciprocal duty elimination negotiations during the Uruguay Round of Multilateral Trade Negotiations (the "Uruguay Round"). A similar agreement between the United States and 16 other major trading coun­ tries eliminating tariffs on enumerated pharmaceuticals and chemical intermediates was implemented for the United States on April 1, 1997, by Proclamation 6982, adding such goods to the scope of the agreement on pharmaceutical products reached at the conclusion of the Uruguay Round and reflected in Schedule XX-United States of America, an­ nexed to the Marrakesh Protocol to the General Agreement on Tariffs and Trade (1994) (Schedule XX). 4. Section 111(b) of the Uruguay Roimd Agreements Act (URAA) (19 U.S.C. 3521(b)) authorizes the President to proclaim the modification of any duty or staged rate reduction of any duty set forth in Schedule XX for products that were the subject of reciprocal duty elimination negotiations during the Uruguay Roimd, if the United States agrees to such action in a multilateral negotiation under the auspices of the WTO, and after compliance with the consultation and layover require­ ments of section 115 of the URAA (19 U.S.C. 3524). Section 111(b) also authorizes the President to proclaim such modifications as are nec­ essary to reflect such duty treatment in Schedule XX by means of rec­ tifications thereof. 5. On April 29, 1999, pursuant to section 115 of the URAA, the United States Trade Representative (USTR) submitted a report to the Com­ mittee on Ways and Means of the House of Representatives and the Committee on Finance of the Senate ("the Committees") that sets forth the proposed tariff eliminations, together with the advice received from the appropriate private sector advisory committee and the United States International Trade Commission regarding the proposed tariff 113 STAT. 2106 PROCLAMATION 7207^JULY 1, 1999

eliminations. During the 60-day period thereafter, the USTR consulted with the Committees on the proposed actions. 6. Section 604 of the Trade Act, as amended (19 U.S.C. 2483), author­ izes the President to embody in the Harmonized Tariff Schedule of the United States (HTS) the substance of the relevant provisions of that Act, and of other acts affecting import treatment, and actions there­ under, including the removal, modification, continuance, or imposition of any rate of duty or other import restriction. 7. Pursuant to section 111(b) of the URAA, I have determined that Schedule XX should be modified to reflect the implementation by the United States of the multilateral agreement on certain pharmaceuticals and chemical intermediates negotiated rmder the auspices of the WTO. In addition, I have determined that the pharmaceuticals appendix to the HTS should be modified to reflect the duty eliminations provided in such agreement, and to make certain minor technical corrections in the identification of particular products in order to ensure that prod­ ucts are accorded the intended duty treatment. NOW, THEREFORE, I, WILLIAM J. CLINTON, President of the United States of America, acting vmder the authority vested in me by the Con­ stitution and the laws of the United States, including but not limited to section 2424(b)(2) of Public Law 106-36, section 111(b) of the URAA, and section 604 of the Trade Act, do hereby proclaim that: (1) Nondiscriminatory treatment (normal trade relations treatment) shall be extended to the products of MongoUa, which shall no longer be subject to title IV of the Trade Act. (2) The extension of nondiscriminatory treatment to the products of MongoUa shall be effective as of the date of signature of this proclama­ tion. (3) In order to implement the multilateral agreement negotiated under the auspices of the WTO to eliminate tariffs on certain pharma­ ceutical products and chemical intermediates, and to make technical corrections in the tariff treatment accorded to such products, the HTS is modified as set forth in the Annex to this proclamation. (4) Such modifications to the HTS shall be effective with respect to articles entered, or withdrawn from warehouse for consumption, on or after the dates set forth in the Annex for the respective actions taken. (5) Any provisions of previous proclamations and Executive orders that are inconsistent with the actions taken in this proclamation are su­ perseded to the extent of such inconsistency. IN WITNESS WHEREOF, I have hereimto set my hand this first day of July, in the year of our Lord nineteen hundred and ninety-nine, and of the Independence of the United States of America the two hundred and twenty-third.

WILLIAM J. CLINTON PROCLAMATION 7207-JULY 1, 1999 113 STAT. 2107

ANNEX

MODIFICATIONS TO THE HARMONIZED TARIFF SCHEDULE OF THE UNITED STATES

The Hannonized Tariff Schedule of the United States (HTS) U modified as provided herein, effective on the dates set forth for each annex section.

Section A. Effective with respect to articles entered, or withdrawn from warehouse for consumption, on or tafte r July 1. 1999. the followinn products lire to be accorded dutv- free treatment:

1. For subheading^ s 290S.5.22.50.2910.30.00.2921.43.40: , 2922.19.20.2924.29.0S.wd 2933.39.20 the Rites of Du^ 1-Specul subcolunm is modined by insetting, in ilplnbetical order, the symbol "K" m the parentheses following the "Free" rate of duty in stich subcolumn tor each sudi subboding. 2. The Pharmaceutical Appendix to the HTS is modified as provided below: M. TiMe I of the Appendix is modified by adding the following new INN::, in alphabetical order, in the "noduct" column and theji- CAS numbers m the "CAS No." column:

Product CAS Number 136470-7»4 eperezolid 163800-04-4 128638-7M 107724-20-9 1S36S2-3S-7 148031-34-9 15422S-1M 12354»4e-1 129300-27-2 aumiialaliiia 13S112-7»-2 bndofloxacin 164130-994 •wiofloKacin 157182-32-6 ianlimomab 167S16-91-3 alnartrw 154541-72-7 fasidatril 13S038-37-2 ahnoMplan 15432M7-6 ftscracetHn li093S-19-3 •knuiWa 61136-12-7 fehnzumab 167747-20-8 123013-22-8 12236448-7 fexofenadine 83799-24-0 13S00M 141725-10-2 I3S773-S94 139886-32-1 113 STAT. 2108 PROCLAMATION 7207—JULY 1, 1999

Annex (con.) -2-

Section A (con.) 2. (con.) (a), (con.) Product CAS Number 'roduct CAS Number milfasartan 148564-47-0 ritonavir 155213-67-5 milodistim 137463-76-4 rituximab 174722-31-7 minaJreslat 129688-50-2 123441-03-2 minodronic acid 127657-42-5 144034-80-0 miproxifene 129612-87-9 169758-66-1 145375-43-5 roflumilast 162401-32-3 mivobulin 122332-18-7 rosiglitazone 122320-73-4 moxifloxacin 151096-09-2 roxffiban 170902-47-3 moxilubant 146978-48-5 rupatadine 158876-82-5 nagrestipen 166089-33-4 159912-53-5 105816-04-4 samarium (153 Sm) lexidronam 154427-83-5 nelfmavir 159989-64-7 sampatrilat 129981-36-8 nelzarabinc 121032-29-9 saredutant 142001-63-6 nepadutant 183747-35-5 scopinast 145574-90-9 nepafenac 78281-72-8 seocalcitol 134404-52-7 nepaprazole 156601-79-5 sevelamer 52757-95-6 nepicastat 173997-05-2 sibrafiban 172927-65-0 nerelimomab 162774-06-3 sildenaiil 139755-83-2 nifckalant 130636-43-0 silperisone 140944-31 -6 nolatiexed 147149-76-6 sinapultide 138531-07-4 nolpitantium besilate 155418-06-7 sinittodil 143248-63-9 nonacoe alfa 113478-33-4 sipatrigine 130800-90-7 oberadiTol 114856-44-9 sitafloxacin 127254-12-0 omapatrilat 167305-00-2 sivelestat 127373-66-4 omiloxetine 176894-09-0 soretolide 130403-08-6 opanixil 152939-42-9 sulesomab 167747-19-5 opratonium iodide 146919-78-0 sunepitron 148408-65-5 oprelvekin 145941-26-0 talUrelin 103300-74-9 orazipone I37I09-78-5 talviraline 169312-27-0 orboiiban 163250-90-6 targinine 17035-90-4 osanctant 160492-56-8 tasonermin 94948-59-1 osutidine 140695-21-2 131987-54-7 pagocione 133737-32-3 technetium (99m Tc) nofetumomab palinavir 154612-39-2 merpentan 165942-79-0 135729-56-5 technetium (99m Tc) pintumomab 157476-76-1 pamaqueside 150332-35-7 technetium (99mTc) apcitide 178959-14-3 pamiteplase 151912-42-4 temivenne 173324-94-2 paricalcitol 131918-61-1 temocaprilat 110221-53-9 pegmiuinidin 186638-10-8 terbogrel 149979-74-8 peldesine 133432-71-0 tererstigmine 147650-57-5 pclubiprofen 69956-77-0 ticolubant 154413-61-3 pemetrexed 137281-23-3 tifacogin 148883-56-1 perifosine 157716-52-4 tilnoprofen arbamel 159098-79-0 pexiganan 172820-23-4 tivirapine 137332-54-8 pibutidine 103922-33-4 tobicillin 151287-22-8 pifonakin 112721-39-8 trafermin 131094-16-1 pleconaril 153168-05-9 trastuzumab 180288-69-1 pralmotelin 158861-67-7 trecovirsen 148998-94-1 pnunlintide 151126-32-8 tresperimus 160677-67-8 pranazepide 150408-73-4 upenazime 95268-62-5 148553-50-8 urokinase alfa 99821-47-3 pnicalopride 179474-81-8 valganciclovir 175865-60-8 pumaprazole 158364-59-1 valnemulin 101312-92-9 111974-69-7 valspodar 121584-18-7 quilosUgmine 139314-01-5 vatanidipine 116308-55-5 raltitrexed 112887-68-0 141575-50-0 ranelic acid 135459-90-4 vinflunine 162652-95-1 156137-99-4 135354-02-8 resocortol 76675-97-3 xemilofiban 149820-74-6 150812-12-7 107452-89-1 revatropate 149926-91-0 zinostatin stimalamer 123760-07-6 rifalazil 129791-92-0 139264-17-8" rismorelin 146706-68-5

(b). Table 2 of the Appendix is modified by adding the following chemical or INN derivative names in alphabetical order: •BENZOATE DIRJMARATE DIPIVOXIL

(c). Table 3 of the Appendix is modified by adding the following product names, in alphabetical order, along with their CAS numbers:

Product CAS Number

•(S)-*)ut-3-yn-2-ol 2814-6»-4 2-<4-fluoroDenzynthioph«ne 63877-96-3 S-wnino-N.^f-bis(^-acstoxy- 1 -oxamide 33288-71-0 (5«R,11bS)^,10-diini«ioxy-2-PH)pyM.5,5«.6.7,11b-h«(ahydrobenzo{f|lhieno[2,3<]- qulnotna hydrochloiide 178357-37-4 mathyl N-(ph«noxycart>onyl)-l.-vallnate 153441-77-1 (4~>«4luoro-1-nMt(hyM-oxo-7-quinoline-3.caiboxylic add 119916-34-6 PROCLAMATION 7207-^ULY 1, 1999 113 STAT. 2109

Annex (con.) -3-

SectionA. (con.) 2. (con.) (c). (con.)

Product CAS Number

2-iTieFcapto-5--lH-1,4-t>anzodlazapln-2(3H)-one 2886-65-9 2-bro(no-4'-chloro-Z-<2-nuorobenzoyl)acetanillda 1584-62-9 2'-t>eiuoyl-2-bromo-4-chloroac*tandide 41526-21-0 (RS)-(annohydrazid« hydrochloride 55819-71-1 2,3,4-trihydrexyt>enzaldehyda 2144-08-3 dimethyl chloiomalonate 28868-764 4,6oxylate 1 .l-dksxide 59804-25-0 tert-l>irtyl(1S,9S)-6,10-dloxo-9-phthalimidooctahydropyridazo{1,2-aK1,2]diaziipine-1-cart>oxylate 106928-72-7 ethyl (R)-2-hydn>xy-4-phenytt)utyrata 90315-82-5 1-benzyl hydrogen (SH-phthalimidoglutarata 88784-33-2 (S)-1-onyl)hexahydropyridazine-3-cart>oxylic acid 65632-62-4 methyl {(1S^RM-t>enzyl-3-{(3S,4aS;SaS)-3-

Annex (con.)

Section A. (con.) 2. (con.) (c). (con.) Product CAS Number thymidine 50-89-5 3-fnathyl-4-(2,2,2-trifluoraethoxy)-2-pyridyiniethanol 103577-66-8 3-(cyanoimino)-3-piperidlnopropiononitrile 56488-00-7 N-ac8tyl-3-(3,4^lniethoxyph«nyl)-DL-alanine 27313-65-1 2,5,7,8-tetramatliyl-2-<4-nitrophanoxymetliyl)-4-oxochroman-6-yl acetate 107188-34-1 methyl 4--2-{4-{I(2,7-dlmethyl-4-oxo-1,4-dihydroquinazolin-6-y1)methyl](prop-2-ynyt)amlno}- 2- nuorobenzamido)- 4-<1H-tetrazol-5-yl)butyric acid 153537-73« SC-59735 116638-334 SC-70935 193700-51-5 6,7KJichloro-2,3-dimethoi(yquinoxalin-5-ylamina 178619-89-1 4-<2-mathyl-1H-imidazor4,S-c]pyridln-1-yl)benzoic add 132026-12-1 mathyl(4'-nitrDphenethyl)aminanydroch1orid—t .... ,.—•-- -•'iy()amlnenydrochlorid«a 166943-39-1 2-chloroethyl 4-nitrophenyinyle'"l ethe"r 3383-72-0 (2RS,3SR)-2-(2,4-dinuoroph«nyl)-3-(5-fluoropyrimidin-4-yO-1-<1H-1,2,4-triazol-1-yl)butaniroph< - 2-ol-(1R,4S)-2-oxobomane-l6-sulfoniomar c add (1:1) 188416-34-4 6-elhyJ->fluoropyrimidin-4(iv4(11l H)-one 137234-87-8 diphenyl[(S)-pyrrolidin-3-y<]acetonitrile hydrobromide 194602-27-2 (2,3^inyarobenzofuran-5-yl)acetic add 69999-16-2 cydohaxylammonium 1 -{(S]h-2-onyl)-3-<2-methoxyethoxy)propyl]- mdopentanecartioxylata 167944-94-7 d*-4-(benzyloxycart)onyl)cyclohexylammonlum tosylate 87299-45-0 5-bromo-3-({R)-1-mdthYlpyiTOlldin-2-ylmethyl]indole 143322-57-0 me*o-3-benzyl-C-nitro-3-azabicydo(3.1 .Olhexana 151860-16-1 diethyl (6-c>iloro-9H-carbazol-2-yl)melhylmalonate 71208-55-4 beta-cydodextrin sulfobutyl ethers, sodium salt* 182410O0-0 N-<2-cnloroethyl)pyrTolidina hydrochloride 7250.67-1 6,7-bl*(2-methoxyethoxy)qulnazolin-4( 1 H)-one 179688-29-0 ethyl 3,4-dihydroxybenzoate 3-((2)-144-(2-dimethylaminoethoxy)phanyl]-2-phenylbut-1 -enyl}phenol 83647-29^ 2-{l-(terf-butoxycart)onyl)-4-piperidyl]acatic acid 157688-46-5 4-pyndylaoetic add hydrochloride 6622-91-9 8,a,a-trmuoro-4-nltfO-m-toluidine 393-11-3 methyl1-(2,3,5-trK>-acetyl-beta-D-ribofuranosyl)-1H-1,2,4-triazole-3-carboxylate 39925-10-5 ffa-fteit-butoxycarbonyn-ffw-nitix^-L-arginlne 2188-18-3 N'a-(tait-butoxycatbonyl>-N-m«thoxy-N-methyl-N'w-nitro-L-argininamide 139976-34-4 (2S,3S)-3-amlno-2-ethoxy-N-nitropiperidine-1-cart>oxamidine hydrochloride 180250-77-5 (S)-0-benzyllaclaldehyde-N-nyl)hydrazone 192802-28-1 phenyl {4-l4-<4-hydroxyphenyl)piperazin-1-yl]phenyl)carbamate 184177-81-9 r(3S.teV«-(2.4Airifluorophenyl)^1H-1,2,4^iwol-1-ylmethyl)tetrahydro^ 4-chlorobenzenesulronats 175712-02-4 8-chloro-11 -(4-plperidylldene)-5,6-dihydro-11 H-benzo[5,6jcyclohepta[1,2-b]pyridine 100643-71-8 2-hydroxy-2-mathyl-4'-nitro-3--2-quinolyl)vinyqphenyO-3-oxopropyl)Mnzoate 149968-11-6 2-<2-wtyl-2Htetrazol-S-yl)phanylboronic ado 143722-25-2 (3aS.8aR)-3^(2R,4S)-2-bcnzyl-4,S-epoxyvaleryl]-2,2-dimethyl-3,3a,8,Sa-tetrahydro- 2H -lndano{1,2-d]oxazole 158512-24-4 N-{(4S,6S)-fr^nethyl-7,7-dioxo-5,6-dlhydro-4H-thieno[2,3-b]thlopyran-4-yl]acetamide 147086-83-7 N4(4S,6S)-6-methyJ-77-dloxo-2-sulfamoyl-S,6^lhydro-4H-thleno[2.3-b](hiopyran-4-yqacetami^ 147200-03-1 696-07-1 Kri-methyi-IH-pyrazoie-l-cartMxamldine hydrochloride 59194-35-3 (S)-tetrahydroruran-3-ol 86087-23-2 ethyl 4,6^ichloro-3-fomnylindole-2-carboxyIate 153435-96-2 3-oxoandrost-4-ana-17-beta-catboxylic add 302-97-6 alpha,alpha,alpha,alpha',alpha',alpha'-hexafluoro-2,5-xylidine 328-93-8 (i)-2-azablcydo(2.2.1Jhept-5-en-3-one 61865-48-3 (1R,4S)-2-azabicy( . 1 ]hept-S-en-3-one 79200-56-9 H1S,4R)-4-(2-amm loro-9H-purln-9-yl)cyclopent-2-enyl]methano__ l hydrochlorida 172015-79-1 '<2-amlno-4,6-dichloropy(imidin^yl)fonT)anriida 171887-03-9 4-fluorobenzyl• •4- e 87483-29-2 2-amino-3-pyridyl methyl ketone 65326-33-2 6-mathoxy-lH-purin-2-ylannine 20535-83-5 l,3H)-dione 3083-77-0 dioxolan-4-yl]valeric add 157518-70.2 171764-07-1 nitro-4-pyrldone 5435-54-1 2,6-dHluorobenzylamine 69385-30-4 L-dbose 24259-59-4 (5,6-dlchloro-1 H-benzimklazol-2-yl)isopropylamine 176181-55-0 lR)-2-amino-2-ethylhexan-1 -d 151851-75-1 3-(nethylenecydooutanecart)onitrile 15760-35-7 44eit-butylbenzyl 2-{(2R.3S)-3^rR)-1-(tert-butyldimethylsilyloxy)ethyl]- 2-{(1R,3S)-3-methoxy- 2-oxocyelohexyfl-4-oxoazetlalii-1 :yn-2-oxoacetate 159593-17-6 methyl (3aR,4R,7aR)-2wnethyJ-4-((1S,2R)-1,2.3-triacatoxypFopyn-3a,7a-dihydn>-4H-pyrano- RU-dioxazole-e-cartMxylate 78850-37-0 (4S,5R,6R)-5-acetamido-4-amino-6-((1 R,2R)-1,2,3-trihydroxypropyl]-S,6-dihydropyran- 2 -carboxylic add 13052542-1 PROCLAMATION 7207—JULY 1, 1999 113 STAT. 2111

Annex (con.) -5-

Section A. (con.) 2. (con.) (c). (con.)

4023-02-3 J-ac8toxy-5-acetylbenzyl acetate 24085-06-1 (R)-1,2,3,4-tetrahydropapaverine hydrochloride 54417-53-7 tran»-2-cnloro-3-{4-(4-chlorophenyl)cyclohexyl]-1,4-naphthoquinone 153977-22-1 1,3-dichloroacetone 534-07-6 3,5-dimelhylpiperidine 35794-11-7 2,6-diaminopyrimidin-4-ol 56-06-4 1-(2-chloroethyl)piperidinium chloride 2008-75-5 diethyl L-qlutamate hydrochloride 1118-89-4 tert-butyl (1 R,4S)-4-(hydroxymethyl)cyclopent-2-enyleart)amate 168960-18-7 2-butyl-1,3-diazaspirol4.4]non-1-en-4-one hydrochloride 151257-01-1 tert-butyl 2-{[1 -(2-aminothiazol-4-yl)-2-(benzisothiazol-2-ylthio)-2-oxoethyliden«il aminooxy}- 2-nnethylpropionate 89604-92-2 bi$[(i»opropyioxycarbonyloxy)methyl t(R)-2-(6-amino-9H-purin-9-yl) -1 -methylethoxylmethyl phowhonate-fumanc acK) (1:1) 202138-50-9 (R)-{2-(6-amino-9H-purin-9-yl)-1 -methylethoxylmethylphosphonic acid 147127-20-6 (R)-pfopylene cartwnate 16606-55-6 6-amino-9H-purin-9-ylethanol 707-99-3 (R)-2-(S-aniino-9H-purin-9-yl)-1-methylethanol 14047-28-0 chloromethyl isopropyl carbonate 35180-01-9 diethyl (tosyloxy)methylphosphonate 31618-90-3 'R)-3-chloroprbpane-1,2-diol 57090-45-6 S)-Utrityloxy)methyl]oxirane 129940-50-7 S)-z-(2-amino-5-chlorophenyl)-4-cyclopropyl-1,1,1-trifluorobut-3-yn-2-ol 154598-58-0 10,10-bis((2-fluoro~4-pyridyl)n)ethyl]anthrone 160588-45-4 (S)-N-{(1S,2R)-3-[(1,34)enrodioxol-5-ylsulfonyl){isobutyl)amino]-1-benzyl-2-hydroxypropyl}- 3,3-oimethyl-2--1-{(3-amino-1H-indazol-5-yl)methyll-4,7-dibenzyl-3-butyl-5,6- dihydraxyhexahydro-2H-1,3-dlazepin-2-one 188978-02-1 (2S)-Nq(R)-f-<1,3-benzodioxol-5-Yl)butyll-3,3-diethyl-2-{4-{(4-methy1piperazin-1-yl)- carbonyl]phenoxy}-4-oxoazetidine-1-cartx)xamiae 157341-41-8 2-(piperazin-1 -yl)pynmidine 20980-22-7 4-bromo-2,2-diphenylbutanenitrile 39186-58-8 bromoniethylcyclopropane 7051-34-5 cydobutanecartwxylic acid 3721-95-7 * -•• —' ~ -'-• •—•--••J|g 5005-36-7 'ridor4,3-b]indol-1-one 122852-75-9 6-dihydro-2-pyridone 139122-76-2 4,S,6,7-tetrahydrothieno(3,2-c1pyndine hydrochloride 28783-41-7 methyl 2-(2-cnlorophenyl)-2-(4,5,6,7-tetrahyd roth ieno[3,2-c)pyridin-5-yl)acetate hydrochloride 130209-90-4 2-bromo-2-(2-chlorophenyl)acetic acid 141109-25-3 di*odium(2S,3R)-2^iydro)n-3-isobutylsuccinate 157604-22-3 7-amino-3-<2-furoylthiomethyl)-3-cephem-4-carboxylicacid 80370-59-8 methyl 5-chloro-o-anisate 33924-48-0 4-{(4-mesylamino)phenylH-oxobutyric acid 100632-57-3 benzyl (3-Tluoro-4-morpnolinophenyl)carfoamate 168828-81-7 (3R)-3-{(S)-1-(methylamino)ethyllpyrrolidine 155322-92-2 (4-cart)oxybutyl)tripnenylphosphonium bromide 17814-85-6 J3aS,9aS,9bro-3a-methyl-6^2-(2,5,5-trimethyl-1,3-dioxa^-2-yl)ethyl]-1,2,4,5,8,9,9a,9b- octahydro-3aH-cydopenta[ajnaphthalene-3,7-dione 88128-61-4 2-amino-2',5-dichiorobenzophenone 2958-36-3 21-<:hloro-l6-alpha-methylpregna-1,4,9(11)-triane-3,20-dione 151265-34-8 3,20-dioxopregna-1,4,9(11),1&-tetraen-2l-yl acetate 37413-91-5 uracil 66-22-8 tetrabutylammonium (6-iodo-1 H-purin-2-yhamide 156126-48-6 •1S,2S,3S)-2,3-b •• •• '- 132294-17-8 S-miethyluridine 1463-10-1 jenzyl(1-carban . 91558-42-8 5,8-dihydro-1 -naphtt _ 27673-48-9 potauium (R)-N-(3-ethoxy-1-methyl-3-oxoprop-1-enyl)-2-phenylglycine 961-69-3 triethylaniline 33881-72-0 1-(4-(2-din)ethylaminoethoxy)[14C]phenyl)]-1,2-diphenylbutan-1-ol 82407-94-1 o-chlorothlophenol 6320-03-2 cytidine S'-idihydrogen phosphate) 63-37-6 2-{benzyl(tnethyl)amino)ethy... (tnethyl)amlno)ethylr1 acetoacetat- '- e 54527-65-0 2-fnethyl-. 11-nitrosoindolin -nitrosoindt ""e 85440-79-5 inoaininosine 5'-di«odiuS'-disodium pphosphatt , e 4691-65-0 4-{1-hydrpxy-2-(methylamina)ethyl]phenol-L.-tartari' c acid (2:1) 16589-24-S 4-phenylpiperidin-4-o( 40807-61-2 1-{4-benzyloxyphenyl)-2-(4-hydroxy-4-phenyl-1-piperidyl)propan-1-one 188591-61-9 7-chloro-2-<4-methoxy-2-methylphenyl)-2,3-dihydro-SH-pyridazino[4,5-b]quinoline-1,4,10-trione, sodium salt 170142-29-7 N'-(N-methoxycarbonyl-L-valyl1-N 3,3,3-trifluoro-1 -isopropyl-2-oxopropyl]-L- prolinamide 182073-77-4 3-methyl hydrogen 7-chloro-1,4-dihvdro^^xoqulnoline-2,'3-dicarboxylat' ioline-2,3-dicarboxylatee 170143-39-2 (S>-N-(5-(2-(2-amino-4-oxo^,6,7,S-letrBhydro-1H 'Pyrimido[5.4-bl[1,4]thiazin-S-yl)ethyl} •2-thenoyl]. L-glutamic acid 177575-17-6 192329-42-3 9002-12-4 139592-99-7 '2-enyn-N.ethylcyclohexylamine hydrochloride 132173-07-0 (dimetnylamino)ethyl]axime-fumsiric acid (2:1) 130580-02-8 ..M^ ,.—~.«.,... yrr-~..,-—,..-K»'Pyfidazin-3-yl)propane-1.2-diamine-fumancacid (2:3) 137733-33-6 2-tt1 -(7-chloro-4-quinolyl)-5-<2.6-dimethoxyphenyl)-1 H-pyrazol-3-yl]carbonyliimino)- adamantane-2-ca(t>oxylic acid 146362-70-1 (S)-N-(4-(4-acetamldo-4-phenyl-1-piperidyl)-2-(3,4-dichlorophenyl)butyl]-N-niethylbenzamide- 176381-97-8 N'-((2R.3S)-5-chloro-3-(2-chlorophenyl)-1-[(3,4-dimethoxyphenyl)sultonyl]-3-iydroxy-2,3- altiydro-l H-indol-2-yicart>onyl}-L-prolinamide 1-(6-cnloro-2-2Hpyridyl)-4^lperidylaminf '" ' e hydrochloride ethyl ({7S>-7^^-{[(2Rh2-(3-cnlorophenyl)-2-hydroxyethyl]amino}-5.6,7,8-tetrahydro-2-naphthyloxy)^ . . - acetate hyoro-'-'---'hydrochloride- methyl 0-2-deoxy-6-0-sulfo-2-(sulfoamino)-alpha-D^|lucopyranosyl-(1,4)-0-beta-D- glucopyranuronosyKI ,4)-p-2-deoxy-3,&-di-0-sulfo-2-(sulfoaminoj-alpha-D- -glucopyranosyl- (1,4)-O-2-0-sulfb- alpha-L-idopyranuronosyl-(1,4)-2-deoxy-2-(sulfoaminol- 6--•lpha-D-glucopyranoslde, decasodium salt 3-{[4-(4-amidinophenyt)thiazol-2-yl][1 ;onylamidino)phenyl]thiazol-2-ylH1 -(etnoxycamoriylmethyl)- 4 -pipendynamino) propionate (S)-1-{2-{3-(3,4-diclilorqphenyl)-1-(3-lsopropoxyphenacyl)-3-piperidyl]ethyl}-'l-phenyl- 1 -azoniabicyclo-{2.2.2]oaane chloride 5.<4-chlorophenyl)-1-(2,4-elichlorophenyl)-4-methyl-N-piperidino-1H-pyrazol«-3-carboxamide (R)-N-(1-{3-(1-benzoyt-3-(3,4-dichk)ropnenyl)-3-piperidyllpropyl}-4-phenyl-4H5iperidyl)-N-methyl- 113 STAT. 2112 PROCLAMATION 7207—JULY 1, 1999

Annex (con.) -6-

Section A. (con.) 2. (con.) (c). (con.) Product CAS Number

acstamlde hydrochloride dit«niyll-(2,4KJifluoro(Jh«nyl)-2-(1H-1.2,4.iriazol-1-yl)-1-(iH-1.2,4-tria20l-1-ylmethyl)«thyl phosphate (S)-2-^3^(2-(luorob•nzyl)»ulfonylalninol-2-oxo-2,3-dihyd^o-1-pyridyl)-N-(1-fo^myl- 4 -guanidlnobutyl)acatatTiide 4-[4-(434-{(3R,5R)-S-(!i.4-di(lucrophenyl)-5-(1 H-1,2,4-tna20l-1 -ylmelhyljtetrahydrofuran- 3-yirnethyloxy]phenyl)piperazin-1-yl)phenyq-1-[(1S,2S)-1-«thyl-2-hydroxypropyl]-

193275-84-2 193275-85-3 137246-21-0 142034-92-2 21472-89-9 'tetrahydroqulnazolin-1-yll acetate 112733-28-5 2,6-diisopropylphenyl sulfamate 92050-02-7 diethyl (1-cyano-3-methylbutyl)nnalonate 186038-82-4 2-iniino-1.3-thia2ol-4-or» 556-90-1 3,5.di-le(t-butyM-hydroxybenzaldehyde 1620-98-0 N-(blphenyl-2-yl)-4-l(2-nriethyl-4,5-dihxdro-1H-irnidazo[4,5-d][1)benzazepi(i-6-yl)c3rboiiyl]benzarnidd 79528-39-3 3-(aminoniethyl>-5-methylh«xanoicacid 128013-69-4 .\ ...... ,. 4276-85-1 , . . , nyta „, 182149-25-3 ri R,4S)-1 -azabkyclori.2.1]heptan-^ne 142034-97-7 3-anilno-7-iTiethyt-5-pneny(-1H-1,4-ben2odlazepin-2(3H)-one 70890-50-5 1 -ethyl-l ,4-diphenylbul-3-enylamlne 129140-12-1 sodium 1,2,3-t(tazole-5-thk>ut1,2,3-triazole-5-thiolate 59032-27-8 (3-et)!ynylphenyl){6,7-bit(2-inethoxyethoxy)quinazolin-')quinazolin-4-yl1amin' e hxdrochloride 183319-69-9 H(1S,2S)-2-hydroxy-2-<44i¥droxyphenyl)-1-methylethl-methylethylH-phenylpiperldinj - 4-ol mathanesulfonafe tnnydrattiydra'te 189894-57-3 (5R6S)-6-phenyl-5-L4-(2-pyrrolidinoethoxy)phenyl]-5,6,7,8-tetrahydro-2-naphthol- (•) -tartaric add (1:1) 190791-29-6 1-[(S)-3-

Annex (con.) -7-

SectionA. (con.) 2. (con.) (c). (con.) Product CAS Number

(2R.4R)-4^2,&enzyl-5,6.dihydroxyhexahydrc-2H-1,3-diazepin-2.one dimothanMunbnate 177932.69-7"

Section B. Effective with respect to articles enteryi. or withiirawn frorpwarehous e for consumption, on or after April 1.1997. the followuig technical corrections are made to the enumerated subheading:

1. For subheading 2918.13.S0, the Rates of Du^ 1-Special subcoiumn is modified bv inserting, in alphabetical order, the symbol K" in the parentheses folio wmg die "Free" rate of duty in such subcoiumn. 2. The Pharmaceutical Appendix to the HTS is modified bv adding to Ta]>le 3 of the Appendix the following product, with the product name inserted in alphabetical order in the "Prodiuct" column and its Oiemical Abstracts Service (CAS) registry number in the "CAS No." column: *1-(N2-[(S>-1-«thoxycaitenyl-3-phonylpropylH46-trifluoroacetyllayl)pioline 103300-91.0"

Section C. Effective with respect to articles entered, or withdrawn from warehouse for consumption, on or after January 1.1995. the following technical corrections are made to the enumerated subheadings:

For subheadings 2904.90.47,2917.39.30,2918.29.20. 293S.00.OS, and 3402.20.10, the Rates of Duty 1- Special subcoiumn is modified by inserting, in alphabetical order, me synnbol "K" in the parentheses following the "Free" rate of duty in such subcoiumn for each such subheading.

Proclamation 7208 of July 7,1999 To Facilitate Positive Adjustment to Competition From Imports of Lamb Meat

By the President of the United States of America A Proclamation 1. On April 5, 1999, the United States International Trade Commission (USITC) transmitted to the President a imanlmous affirmative deter­ mination in its investigation under section 202 of the Trade Act of 1974, as amended (the "Trade Act") (19 U.S.C. 2252), with respect to imports of fresh, chilled, or frozen lamb meat, provided for in heading 0204 of the Harmonized Tariff Schedule of the United States (HTS). Under section 202 of the Trade Act, the USITC determined that such lamb meat is being imported into the United States in such increased quantities as to be a substantial cause of the threat of serious injury to the domestic industry producing a like or directly competitive arti­ cle. Fiuther, the USITC, pvirsuant to section 311(a) of the North Amer­ ican Free Trade Agreement Implementation i'^ct (the "NAFTA Imple­ mentation Act") (19 U.S.C. 3371(a)), made negative findings vkrith re­ spect to imports of lamb meat from Canada and Mexico. The USITC also transmitted to the President its recommendation made pursuant to section 202(e) of the Trade Act with respect to the action that would address the threat of serious injury to the domestic industry and be most effective in facilitating the efforts of tJie domestic industry to make a positive adjustment to import competition.